news

Antisense oligonucleotide with potential to combat COVID-19 developed

Scientists have designed a compound named ASO-1 that could help to reduce immune response overactivation in patients with COVID-19.

COVID-19

Scientists from Nanyang Technological University (NTU), Singapore, have created a compound that could help to reduce the body’s immune response overactivation without impairing its entire reaction, including when fighting COVID-19.

According to the researchers, an overactive immune system leads to many autoimmune disorders such as rheumatoid arthritis and type 1 diabetes. More recently, it has also been linked to severe COVID-19 infections, in which immune-system signalling proteins ramp up to dangerous levels, leading to damage to the body’s own cells.

The team discovered their molecule from over 200 compounds, which were designed based on their in-house expertise on nucleic acids. The compound designed by the team, called ASO-1, targets tyrosine kinase 2 (TYK2), a member from the Janus kinase (JAK) family of enzymes that play a key role in regulating the body’s immune response. Recent studies have shown that high levels of TYK2 have been associated with severe COVID-19.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

ASO-1 is an antisense oligonucleotide (ASO). ASOs are a type of RNA therapeutics – they target the messenger RNA (mRNA), which carries genetic instructions that cells ‘read’ to make proteins. ASO-1 is designed to bind to TYK2 mRNA, thus preventing cells from producing TYK2 protein.

Through lab experiments using human cells grown in a dish, the scientists found that ASO-1 potently reduced TYK2 levels over a sustained period and inhibited immune signalling pathways that have been associated with autoimmune disorders. They also observed that the compound had no effect against other JAK proteins.

“ASO-1 could be a therapeutic agent worth investigating further. We are planning to conduct further pre-clinical work to validate its therapeutic potential,” said Dr Lim Kah Wai, co-lead author of the study.

The findings on COVID-19 were published in ImmunoHorizons.

Related conditions

Related people

Leave a Reply

Your email address will not be published. Required fields are marked *